Alpha 2.0
Login Register
» Articles » PMID: 16837684

Risk-benefit Profiles of Raloxifene for Women

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2006 Jul 14
PMID 16837684
Citations 7
Authors
Marcia L Stefanick
Affiliations
Soon will be listed here.
Citing Articles

Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.

Timmermans-Sprang E, Gracanin A, Mol J Front Vet Sci. 2017; 4:53.

PMID: 28451590 PMC: 5389977. DOI: 10.3389/fvets.2017.00053.

Evaluating the potential bioactivity of a novel compound ER1626.

Wang L, Zeng Y, Wang T, Liu H, Xiao H, Xiang H PLoS One. 2014; 9(1):e86509.

PMID: 24475135 PMC: 3903524. DOI: 10.1371/journal.pone.0086509.

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.

Ko S, Jordan V Expert Opin Pharmacother. 2011; 12(4):657-74.

PMID: 21294695 PMC: 3085345. DOI: 10.1517/14656566.2011.557360.

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.

Vogel V Clin Interv Aging. 2009; 3(4):601-9.

PMID: 19281053 PMC: 2682393. DOI: 10.2147/cia.s3344.

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Vogel V Expert Rev Anticancer Ther. 2008; 9(1):51-60.

PMID: 19105706 PMC: 2785111. DOI: 10.1586/14737140.9.1.51.